Recently Roche Holding said it has filed an application to the U.S. Food and Drug Administration for a novel cancer drug called trastuzumab-DM1, or T-DM1, the drug hoped could help the Swiss pharma giant replace its Herceptin cure for women with advanced breast cancer. The drug is the first conjugated monoclonal antibody to be reviewed [...]